QQ客服 官方微博 反馈留言

	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer
	Si, Xiaoyan; Zhang, Li; Wang, Hanping; Zhang, Xiaotong; Wang, Mengzhao; Han, Baohui; Li, Kai; Wang, Qiming; Shi, Jianhua; Wang, Zheh 更多
刊名	LUNG CANCER
	2018
卷号	122页码:32-37
关键词	Anlotinib Non-small cell lung cancer Quality of life
DOI	10.1016/j.lungcan.2018.05.013
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4565273
专题	山东大学
作者单位	1.Beijing Union Med Coll Hosp, Beijing, Peoples R China. 2.Shang
推荐引用方式 GB/T 7714	Si, Xiaoyan,Zhang, Li,Wang, Hanping,et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer[J]. LUNG CANCER,2018,122:32-37.
APA	Si, Xiaoyan.,Zhang, Li.,Wang, Hanping.,Zhang, Xiaotong.,Wang, Mengzhao.,...&Wang, Zheh 更多.(2018).Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.LUNG CANCER,122,32-37.
MLA	Si, Xiaoyan,et al."Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer".LUNG CANCER 122(2018):32-37.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。